*June 2023* In June 2023, Lung Cancer Living Room™ gathered experts such as Dr. Karen Reckamp, Judy Johnson, MBA, and Andrew Ciupek, PhD to discuss and demystify the subject of clinical trials for lung cancer. They started by explaining what clinical trials are, emphasizing that they're not limited to drug…

*September 2023* RARITAN, N.J., Sept. 6, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced positive topline results from the three-arm Phase 3 MARIPOSA-2 study evaluating RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), given with and without lazertinib, an oral, third-generation…

*September 2023* This month we have the honor of featuring Paul Stockhammer, MD, PhD. As a third-year resident at Yale School of Medicine last year, Dr Stockhammer received the Distinguished Young Investigator Research Award at the 2022 EGFR Research Summit for his work entitles “Co-occurring Alterations in Multiple Tumor Suppressor…

*July 2023* In the article that accompanies this editorial, Piotrowska et al3 attempt to fill that void with results from a phase I/II study of zipalertinib, an irreversible, oral EGFR TKI in patients with recurrent or metastatic NSCLC harboring EGFR ex20ins mutations. In preclinical models, zipalertinib demonstrated selective inhibition of EGFR ex20ins, with minimal activity…

*July 2023* A University of Kentucky Markey Cancer Center research team identified an existing cancer drug that shows promise as a treatment for the most common type of non-small cell lung cancer. The study published in the American Journal of Cancer Research shows that the Food and Drug Administration-approved medication crizotinib (also…

*June 2023* EGFR The biggest lung cancer news to be presented at this year's meeting was the final 5-year survival results of the ADAURA trial. This trial, the first of its kind, looked at the use of adjuvant (after surgery) osimertinib (a third-generation targeted therapy for EGFR-positive lung cancer) in patients who had…

*June 2023* Rezivertinib (BPI-7711) showed promising clinical central nervous system (CNS) efficacy among patients with advanced non–small cell lung cancer (NSCLC) with EGFR T790M mutation and CNS metastases.​​ The study included individual data from 2 different single-arm, phase 1 (NCT03386955) and phase 2b studies (NCT03812809) to assess the CNS response of rezivertinib…

*July 2023* Benjamin Besse, MD, PhD, professor of medical oncology at Université Paris-Saclay and Head of Clinical Research at Gustave Roussy, discusses the biomarker analysis of cohort D of the phase 1/1b CHRYSALIS-2 (NCT04077463) study. In the trial, the efficacy of amivantamab (Rybrevant) and lazertinib (Leclaza) is being evaluated for…

*July 2023* Targeted therapies and the complex landscape after progression on osimertinib/Tagrisso. You can now watch it on demand here. It's extremely informative! View the presentation slides here.

*July 2023* With osimertinib (Tagrisso) available as a treatment option in both the metastatic and adjuvant settings for patients with EGFR-mutated non–small cell lung cpatients with EGFR-mutated non–small cell lung cancer ancer (NSCLC) and ongoing trials evaluating combination therapies for this patient population, molecular testing to identify these aberrations in patients with…